Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Transfusion. 2014 Nov 2;55(4):864–874. doi: 10.1111/trf.12904

Figure 3. In vitro functional potential of ex vivo expanded MPB cells.

Figure 3

A) Effects of 5azaD/TSA on frequency of CAFC. CAFC frequency was computed using minimization by regression to the cell number at which 37% of wells showed negative CAFC growth with 95% statistical precision. CAFC frequency was similar between 5azaD/TSA + Cytokine A treated MPB cells (15.4 ± 4.8) and unmanipulated CD34+ cells (10.8 ± 1.9). Based on CAFC frequency determined by limiting dilution analyses the mean number of CAFC assayable from 10,000 unmanipulated primary MPB CD34+ cells or 10,000 cells from the whole expansion culture after 9 days started with CD34+ cells was determined. Significantly lower CAFC frequency was observed in MPB cells cultured in Cytokine A alone (0.5 ± 0.2, p=0.036) compared to the unmanipulated CD34+ cells. B) Effects of 5azaD/TSA on CAFC fold expansion. The fold expansion was determined by dividing the number of total CAFC assayed from the culture product at Day 9 by the total number of CAFC assayed from primary CD34+ cells at Day 0. An expansion of CAFC was observed in 5azaD/TSA treated MPB cells (2.2 ± 0.5) while a reduction in CAFC was observed in MPB cells cultured in Cytokine A alone (0.3 ± 0.1) (p =0.1).